What's new? Log in Free sign up

Septerna, Inc. Common Stock (SEPN)

Company Profile

Company profile

Ticker

SEPN

Exchange

CEO

Dr. Jeffrey T. Finer M.D., Ph.D.

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Flying Eagle Acquisition Corp.

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

IRS number

843891440

SEPN stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Regulation FD Disclosure

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

Quarterly report

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Amendments to Articles of Incorporation or Bylaws

Registration of securities for employees

Prospectus supplement with pricing info

Notice of effectiveness

Registration of additional securities for an S-1

Latest ownership filings

View all

Gil M Labrucherie

Change in insider ownership

Change in insider ownership

Gil M Labrucherie

DRIEHAUS CAPITAL MANAGEMENT LLC

Third Rock Ventures V, L.P.

Gil M Labrucherie

Gil M Labrucherie

RA CAPITAL MANAGEMENT, L.P.

Financial summary

Financial statements Chart SEPN financial data

Quarter (USD)	Sep 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
Cash on hand (at last report)			89.15 mm		89.15 mm
Cash burn (monthly)			7.52 mm		(no burn)
Cash used (since last report)			38.20 mm		n/a
Cash remaining			50.95 mm		n/a
Runway (months of cash)			6.8		n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

SEPN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0.00	0.00
Total shares	0.00	0.00
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SEPN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Feb 25	Labrucherie Gil M	Common Stock	Buy	Acquire P	Yes	No	5.85	3,718	21.75 k	40,000
27 Feb 25	Jeffrey Finer	Common Stock	Buy	Acquire P	No	No	5.8	3,000	17.40 k	771,907
26 Feb 25	Jeffrey Finer	Common Stock	Buy	Acquire P	No	No	5.6989	4,000	22.80 k	768,907
25 Feb 25	Labrucherie Gil M	Common Stock	Buy	Acquire P	Yes	No	5.59	6,282	35.12 k	36,282
25 Feb 25	Jeffrey Finer	Common Stock	Buy	Acquire P	No	No	5.6765	10,000	56.77 k	764,907
24 Feb 25	Third Rock Ventures VI	Common Stock	Buy	Acquire P	No	No	5.999	18,861	113.15 k	4,211,659
21 Feb 25	Third Rock Ventures VI	Common Stock	Buy	Acquire P	No	No	5.94	427,668	2.54 mm	4,192,798
21 Feb 25	Labrucherie Gil M	Common Stock	Buy	Acquire P	Yes	No	5.85	5,000	29.25 k	30,000
20 Feb 25	Third Rock Ventures VI	Common Stock	Buy	Acquire P	No	No	5.92	612,674	3.63 mm	3,765,130
20 Feb 25	Labrucherie Gil M	Common Stock	Buy	Acquire P	Yes	No	5.8782	14,500	85.23 k	25,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Wells Fargo Downgrades Septerna to Equal-Weight, Lowers Price Target to $14

Wells Fargo analyst Derek Archila downgrades Septerna (NASDAQ:SEPN) from Overweight to Equal-Weight and lowers the price target from $43 to $14.

Crude Oil Gains 1.5%; Fluor Shares Plunge Following Downbeat Earnings

US Stocks Mixed; NY State Business Activity Rises In February

Cantor Fitzgerald Reiterates Overweight on Septerna, Maintains $50 Price Target

Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

Press releases

From Benzinga Pro

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Septerna, Inc. ("Septerna" or the "Company")

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. ("Septerna" or the "Company") (NASDAQ:SEPN). The investigation concerns whether

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

LOS ANGELES, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Septerna, Inc. ("Septerna" or "the Company") (NASDAQ:SEPN) investors that the firm has initiated an investigation into possible securities

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.